Clinical Trial Update: Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating topiramate as an adjunct to amantadine for dyskinesia in Parkinson's disease was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskinesia
• Parkinson Disease

Drugs mentioned

• Topiramate (Topiramate)
• amantadine (amantadine)

Snippet

Sponsor: Rush University Medical Center | Conditions: Idiopathic Parkinson's Disease, Drug Induced Dyskinesia | Phase 2 | Status: TERMINATED | Results posted: 2019-04-16